title: Overdiagnosing early spondyloarthritis: what are the risks?
authors.affiliation: Service de rhumatologie, Hôtel-Dieu, CHU de Nantes, 44093 Nantes Cedex 01, France. Electronic address: jeanmarie.berthelot@chu-nantes.fr.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Berthelot
authors.forename: Benoît
authors.initials: B
authors.lastname: Le Goff
authors.forename: Yves
authors.initials: Y
authors.lastname: Maugars
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003951:Diagnostic Errors / Q000009:adverse effects*; D006801:Humans; D012307:Risk Factors; D025241:Spondylarthritis / Q000175:diagnosis*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha
keywords: ASAS; Adalimumab; Ankylosing spondylitis; Infraradiological; New York criteria; Spondyloarthritis; TNFα antagonists